Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Krayem, Mohammad; Najem, Ahmad; Journe, Fabrice; Morandini, Renato; Sales, François; Awada, Ahmad; Ghanem, Ghanem E

Krayem, Mohammad; Najem, Ahmad; Journe, Fabrice; Morandini, Renato; Sales, François; Awada, Ahmad; Ghanem, Ghanem E.

Afiliação

Krayem M; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Najem A; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Journe F; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Morandini R; Service d'Anatomie Humaine et d'Oncologie Expérimentale, Université de Mons, Mons, Belgium.
Sales F; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Awada A; Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Ghanem GE; Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Oncotarget ; 9(61): 31888-31903, 2018 Aug 07.

Article em En | MEDLINE | ID: mdl-30159130

Palavras-chave

V600EBRAF; acquired resistance; melanoma; senescence; vemurafenib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Bélgica